Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13960990 | 0.79 | KDR (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3772458 | 0.79 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL28566342 | 0.79 | MAOB (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31487914 | 0.79 | MAPT (0.38) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2281774 | 0.79 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2284618 | 0.79 | PRKAB2 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL12517742 | 0.76 | PRKAB2 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13822288 | 0.75 | KDR (0.68) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18397071 | 0.75 | MAPT (0.35) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1991834 | 0.75 | CDK2 (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523552-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2523552-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8946237-B2 | Pyrazolo[1,5-A]pyrimidines as mark inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2178375-B1 | PYRAZOLOÝ1,5-A¨PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2178375-B1 | PYRAZOLOÝ1,5-A¨PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-8461162-B2 | Pyrazolo[1,5-a]pyrimidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461162-B2 | Pyrazolo[1,5-a]pyrimidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461162-B2 | Pyrazolo[1,5-a]pyrimidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100305091-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305091-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME LLC | 2010-12-02 | — | — | US | disclosed |
| WO-2009014620-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | PRKAB2 321/4885PRKAG1 94/4885PRKAA2 459/4885 |
| US-20100305091-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | MAPT, TTBK1, TTBK2 | PRKAB2 567/4885PRKAG1 441/4885PRKAA2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.